Nanjing Vazyme Biotech Co.,Ltd (688105.SS)
- Previous Close
25.79 - Open
25.93 - Bid 26.52 x --
- Ask 26.53 x --
- Day's Range
25.40 - 26.69 - 52 Week Range
17.58 - 41.49 - Volume
2,452,196 - Avg. Volume
2,574,255 - Market Cap (intraday)
10.608B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.57 - Earnings Date --
- Forward Dividend & Yield 1.25 (4.71%)
- Ex-Dividend Date Jun 7, 2023
- 1y Target Est
42.86
Nanjing Vazyme Biotech Co., Ltd. offers technology solutions for life science, biomedicine, and in vitro diagnostics. The company offers reagents for molecular biology research, such as nucleic acid extraction, PCR, cloning/mutagenesis, nucleic acid electrophoresis, reverse transcription, real-time PCR (qPCR), genome editing, and cell biology/protein research; reagents for NGS library preparation, including automated liquid handling workstation, DNA sequencing, RNA sequencing, single cell-seq series, epigenetics series, beads series, quantification series, and capture series; reagents for molecular diagnosis comprising isothermal amplification reagents, PCR, reverse transcription, real-time PCR, one-step series, and animal detection; and reagents for bio-medicine, such as vaccine effectiveness evaluations and vaccine manufacture. Nanjing Vazyme Biotech Co., Ltd. was founded in 2012 and is based in Nanjing, China.
www.vazyme.comRecent News: 688105.SS
Performance Overview: 688105.SS
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 688105.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 688105.SS
Valuation Measures
Market Cap
10.61B
Enterprise Value
8.47B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.97
Price/Book (mrq)
2.64
Enterprise Value/Revenue
3.97
Enterprise Value/EBITDA
-27.06
Financial Highlights
Profitability and Income Statement
Profit Margin
-1.18%
Return on Assets (ttm)
-0.18%
Return on Equity (ttm)
-0.39%
Revenue (ttm)
1.29B
Net Income Avi to Common (ttm)
-15.12M
Diluted EPS (ttm)
-0.57
Balance Sheet and Cash Flow
Total Cash (mrq)
3.04B
Total Debt/Equity (mrq)
27.07%
Levered Free Cash Flow (ttm)
17.18M
Research Analysis: 688105.SS
Company Insights: 688105.SS
688105.SS does not have Company Insights